Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers (Q34107482)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Razelle Kurzrock

14

object named as

Razelle Kurzrock

1 reference

Europe PubMed Central

31 July 2017

Guillermo Garcia-Manero

13

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

31 July 2017

6

object named as

Aung Naing

1 reference

Europe PubMed Central

31 July 2017

2

object named as

Filip Janku

1 reference

Europe PubMed Central

31 July 2017

author name string

Jennifer J Wheler

1

1 reference

Europe PubMed Central

31 July 2017

Gerald S Falchook

3

1 reference

Europe PubMed Central

31 July 2017

Tiffiny L Jackson

4

1 reference

Europe PubMed Central

31 July 2017

Siqing Fu

5

1 reference

Europe PubMed Central

31 July 2017

Apostalia M Tsimberidou

7

1 reference

Europe PubMed Central

31 July 2017

Stacy L Moulder

8

1 reference

Europe PubMed Central

31 July 2017

David S Hong

9

1 reference

Europe PubMed Central

31 July 2017

Hui Yang

10

1 reference

Europe PubMed Central

31 July 2017

Sarina A Piha-Paul

11

1 reference

Europe PubMed Central

31 July 2017

Johnique T Atkins

12

1 reference

Europe PubMed Central

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 January 2014

1 reference

Europe PubMed Central

31 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

31 July 2017

73

1 reference

Europe PubMed Central

31 July 2017

3

1 reference

Europe PubMed Central

31 July 2017

495-501

1 reference

Europe PubMed Central

31 July 2017

https://scigraph.springernature.com/pub.10.1007/s00280-014-2384-1

0 references

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Bevacizumab in non small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Valproate: past, present, and future.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148903

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2384-1

21 January 2018

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2384-1

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2384-1

21 January 2018

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2384-1

21 January 2018

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2384-1

21 January 2018

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2384-1

21 January 2018

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2384-1

21 January 2018

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435060

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435060

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-014-2384-1

1 reference

Europe PubMed Central

31 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34107482&oldid=1752698634"